NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis
Drug-induced liver injury (DILI) is the most common adverse drug reaction in the treatment of tuberculosis (TB). Several studies showed that patients with TB and the slow-acetylator phenotype caused by NAT2 variants are highly susceptible to DILI caused by anti-TB drugs, hereafter designated AT-DILI. However, the role of NAT2 variants in AT-DILI has never been assessed for an Indonesian population. We recruited 50 patients with TB and AT-DILI and 191 patients with TB but without AT-DILI; we then used direct DNA sequencing to assess single-nucleotide polymorphisms in the coding region of NAT2. NAT2*6A was significantly associated with susceptibility to AT-DILI (P=7.7 × 10(-4), odds ratio (OR)=4.75 (1.8-12.55)). Moreover, patients with TB and the NAT2-associated slow-acetylator phenotype showed higher risk of AT-DILI than patients with the rapid- or intermediate-acetylator phenotypes (P=1.7 × 10(-4), OR=3.45 (1.79-6.67)). In conclusion, this study confirms the significance of the association between slow-acetylator NAT2 variants and susceptibility to AT-DILI in an Indonesian population.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Journal of human genetics - 61(2016), 6 vom: 25. Juni, Seite 533-7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yuliwulandari, Rika [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antitubercular Agents |
|---|
| Anmerkungen: |
Date Completed 06.04.2017 Date Revised 30.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/jhg.2016.10 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM257808043 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM257808043 | ||
| 003 | DE-627 | ||
| 005 | 20231224183630.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/jhg.2016.10 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0859.xml |
| 035 | |a (DE-627)NLM257808043 | ||
| 035 | |a (NLM)26911349 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yuliwulandari, Rika |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.04.2017 | ||
| 500 | |a Date Revised 30.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Drug-induced liver injury (DILI) is the most common adverse drug reaction in the treatment of tuberculosis (TB). Several studies showed that patients with TB and the slow-acetylator phenotype caused by NAT2 variants are highly susceptible to DILI caused by anti-TB drugs, hereafter designated AT-DILI. However, the role of NAT2 variants in AT-DILI has never been assessed for an Indonesian population. We recruited 50 patients with TB and AT-DILI and 191 patients with TB but without AT-DILI; we then used direct DNA sequencing to assess single-nucleotide polymorphisms in the coding region of NAT2. NAT2*6A was significantly associated with susceptibility to AT-DILI (P=7.7 × 10(-4), odds ratio (OR)=4.75 (1.8-12.55)). Moreover, patients with TB and the NAT2-associated slow-acetylator phenotype showed higher risk of AT-DILI than patients with the rapid- or intermediate-acetylator phenotypes (P=1.7 × 10(-4), OR=3.45 (1.79-6.67)). In conclusion, this study confirms the significance of the association between slow-acetylator NAT2 variants and susceptibility to AT-DILI in an Indonesian population | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antitubercular Agents |2 NLM | |
| 650 | 7 | |a Arylamine N-Acetyltransferase |2 NLM | |
| 650 | 7 | |a EC 2.3.1.5 |2 NLM | |
| 650 | 7 | |a NAT2 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.3.1.5 |2 NLM | |
| 700 | 1 | |a Susilowati, Retno Wilujeng |e verfasserin |4 aut | |
| 700 | 1 | |a Wicaksono, Britanto Dani |e verfasserin |4 aut | |
| 700 | 1 | |a Viyati, Kencono |e verfasserin |4 aut | |
| 700 | 1 | |a Prayuni, Kinasih |e verfasserin |4 aut | |
| 700 | 1 | |a Razari, Intan |e verfasserin |4 aut | |
| 700 | 1 | |a Kristin, Erna |e verfasserin |4 aut | |
| 700 | 1 | |a Syafrizal |e verfasserin |4 aut | |
| 700 | 1 | |a Subagyo |e verfasserin |4 aut | |
| 700 | 1 | |a Sri Diana, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Setiawati, Suci |e verfasserin |4 aut | |
| 700 | 1 | |a Ariyani, Aziza |e verfasserin |4 aut | |
| 700 | 1 | |a Mahasirimongkol, Surakameth |e verfasserin |4 aut | |
| 700 | 1 | |a Yanai, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Mushiroda, Taisei |e verfasserin |4 aut | |
| 700 | 1 | |a Tokunaga, Katsushi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of human genetics |d 1998 |g 61(2016), 6 vom: 25. Juni, Seite 533-7 |w (DE-627)NLM095504133 |x 1435-232X |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2016 |g number:6 |g day:25 |g month:06 |g pages:533-7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/jhg.2016.10 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2016 |e 6 |b 25 |c 06 |h 533-7 | ||